Jan 19 (Reuters) - BAVARIAN NORDIC A/S:
* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS
* OPEN-LABEL PHASE 1 TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF MVA-BN(Â®) BRACHYURY VACCINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 